Author

Aurélie Maguer

Observed name: Aurelie Maguer

Institution: Innate Pharma (France)

Observed institution: Innate Pharma (France)

ORCID: 0009-0003-5629-1222

Observed ORCID: 0009-0003-5629-1222

OpenAlex ID: A5083038044

Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant

2022 · Olivier Demaria, Laurent Gauthier, et al. · Cell Reports Medicine · 80

A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma

2024 · Olivier Demaria, Guillaume Habif, et al. · Science Immunology · 22

Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK cell engager directed against CD20 for R/R B-NHL, in comparison with a CD20-targeting T cell engager.

2024 · Olivier Demaria, Marie Vetizou, et al. · Journal of Clinical Oncology · 3

Abstract 6582: Preclinical characterization of IPH45, a novel topoisomerase I inhibitor ADC targeting Nectin-4 for the treatment of Nectin-4 expressing tumors

2024 · Romain Remark, Cécile Bonnafous, et al. · Cancer Research · 2

1056 IPH45, a next-generation antibody-drug conjugate (ADC) targeting nectin-4

2024 · Romain Remark, Cecile Bonnafous, et al. · Journal for ImmunoTherapy of Cancer

Works count: 5

Citation count: 107

H-index: 3

I10-index: 2